Singapore’s MerLion Completes Phase III Finafloxacin Studies For Outer Ear Infection, Looks Ahead To Other Indications
This article was originally published in PharmAsia News
Executive Summary
Singapore-based MerLIon Pharmaceuticals has reached another milestone with its finafloxacin antibiotic with the topic form for outer ear infection successfully passing Phase III trials in North America. But the firm is still looking for help taking another indication into Phase III.